Hims & Hers and Eli Lilly announced a partnership on November 6, 2026, giving eligible patients access to Lilly's weight-loss medicines through Hims' online consultation, prescribing, and home-delivery service.[1]
Zepbound and Foundayo help eligible adults lose weight and keep it off. Zepbound (tirzepatide) is a once-weekly injection; Foundayo (orforglipron) is a daily pill. Both are approved by the Food and Drug Administration (FDA) for adults with obesity, or overweight with a weight-related health condition, alongside a reduced-calorie diet and increased physical activity.[1]
Medication | Active ingredient | Format | Starting self-pay price |
|---|---|---|---|
Zepbound | Tirzepatide | Weekly injection | $299 per month |
Foundayo | Orforglipron | Daily pill | $149 per month |
These are Lilly’s existing self-pay prices, rather than an exclusive Hims discount.[1] The drug price is not the full bill, however.
Hims requires a separate weight-loss membership
$39 for the first month, then $149 a month
This is billed apart from the medication and not FSA/HSA-eligible.[5]
A patient on Foundayo should expect roughly $298 a month at the starting dose after month one; a Zepbound patient roughly $448. Lilly’s figures are starting-dose prices, and the announcement does not break out costs at higher doses.[1]
How the Service Works
Hims & Hers connects patients with licensed healthcare professionals through online consultations. Patients submit their health history and treatment goals for a provider to review.[2]
The companies say prescribing decisions will remain independent. A provider must determine whether a medication is appropriate for the patient.[1]
Hims says its weight-loss membership includes 24/7 access to a care team, nutrition guidance, regular clinical check-ins, and an online weight-loss community.[1]
Hims & Hers' Expansion Into Weight-Loss Care
Hims launched in November 2017 at venture studio Atomic. The company identifies Andrew Dudum, Hilary Coles, Jack Abraham, and Joe Spector as its founders.[3] Dudum remains chief executive officer and previously co-founded Atomic Labs.[4]
Its early business focused on men's health, including hair loss and erectile dysfunction. Hers launched in 2018. Hims & Hers went public through a merger with a special-purpose acquisition company in 2021 and acquired Apostrophe and Honest Health that year. The company expanded its weight-loss offerings in 2023.[2]
Why Lilly held out for two years
Lilly spent 2025 building a direct-to-consumer channel, LillyDirect, with telehealth partners like Ro while pointedly excluding Hims. The reason was compounding. Hims began offering compounded GLP-1s in May 2024 and grew into the most visible seller of cheaper, non-FDA-approved copies of Novo Nordisk's semaglutide.
In June 2025, Lilly's chief financial officer said the company would only work with telehealth firms that agreed to stop selling copycat weight-loss drugs, which Bloomberg Law reported made a Hims deal unlikely. Hims had been openly courting Lilly since its Q1 2025 earnings call.
The pressure then came from regulators. In September 2025 the FDA sent Hims a warning letter over website claims that its compounded products contained the same active ingredient as Ozempic and Wegovy. In February 2026 the agency said it intended to restrict the GLP-1 ingredients used in mass-marketed compounded alternatives, and Hims was named directly, as the company disclosed in its Q2 2026 10-Q. Hims responded by shifting its U.S. weight-loss offering toward branded drugs and scaling compounding back to a limited role.
That shift produced a settlement and distribution deal with Novo Nordisk earlier this year, which brought branded Wegovy onto the Hims platform. The Lilly agreement follows the same template.
The Agreement's Compounding Commitment
Hims & Hers also said it has never offered compounded copies of Lilly's glucagon-like peptide-1 (GLP-1) medicines and committed not to offer them in the future. The commitment concerns Lilly's drugs.[1]
The announcement does not disclose financial terms between the companies.[1]
What to watch
Terms. No financial terms were disclosed. Whether Lilly is paying Hims for volume, Hims is buying at a discount, or neither, shapes how durable the partnership is.
Compounded semaglutide. Hims still offers it on a limited basis. If the FDA finishes the restriction it previewed in February, that line of business ends regardless of any Lilly agreement.
The Novo side. Hims now carries both companies' branded drugs. The next question is whether either manufacturer pushes for preferred placement, and whether that squares with the provider-independence language both deals contain.
Price. $299 for Zepbound and $149 for Foundayo are Lilly's list self-pay prices. Any movement there comes from Lilly's pricing strategy, not from Hims.
Sources
Eli Lilly and Company and Hims & Hers Health, Inc. (2026, November 6). Lilly and Hims & Hers expand access to FDA-approved Lilly medicines. Eli Lilly release via PR Newswire. Read the partnership announcement.
Hims & Hers. (Accessed November 7, 2026). About Hims: Modern Men's Healthcare. Hims. Company history and care process.
Hims & Hers. (2020, October 1). Hims & Hers, a Multi-Specialty Telehealth Platform, to Become Publicly-Traded via Merger with Oaktree Acquisition Corp. Hims & Hers investor relations. Founders and public-market transaction announcement.
Hims & Hers. (Accessed November 7, 2026). Executive Management: Andrew Dudum. Hims & Hers investor relations. Andrew Dudum's executive biography.
Hims & Hers. (Accessed November 7, 2026). GLP-1 weight loss medications. Hims. https://hims.com/glp1. Membership fee, billing terms, and FSA/HSA eligibility.

